Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12080962 | 0.98 | L3MBTL1 (0.66) | L3MBTL1ACHEPOLBECE1ALDH1A1 | |
| SCHEMBL23615217 | 0.85 | L3MBTL1 (0.64) | L3MBTL1ACHEPOLBALDH1A1NPC1 | |
| SCHEMBL16450798 | 0.85 | L3MBTL1 (0.50) | L3MBTL1ACHEPOLBECE1NPC1 | |
| SCHEMBL12514043 | 0.84 | KDM1A (0.58) | L3MBTL1POLBECE1NPC1GAA | |
| SCHEMBL18236192 | 0.82 | HPGD (0.54) | L3MBTL1POLBECE1NPC1GAA | |
| SCHEMBL16397272 | 0.82 | ACHE (0.54) | L3MBTL1ACHEPOLBECE1NPC1 | |
| SCHEMBL12852563 | 0.81 | MAOA (0.55) | L3MBTL1ACHEECE1NPC1GAA | |
| SCHEMBL758061 | 0.81 | L3MBTL1 (1.00) | L3MBTL1POLBNPC1RAB9AMAPT | |
| SCHEMBL17895483 | 0.80 | L3MBTL1 (0.62) | L3MBTL1ACHEPOLBALDH1A1NPC1 | |
| SCHEMBL15996505 | 0.79 | L3MBTL1 (0.45) | L3MBTL1POLBALDH1A1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590666-A1 | THIAZOLE DERIVATIVES AS TAU AGGREGATION INHIBITORS | WisTa Laboratories Ltd. (SG) | 2025-07-30 | — | — | EP | disclosed |
| CN-119894874-A | Thiazole derivatives as TAU aggregation inhibitors | 维斯塔实验室有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024061658-A1 | THIAZOLE DERIVATIVES AS TAU AGGREGATION INHIBITORS | WISTA LABORATORIES LTD. (SG) | 2024-03-28 | — | — | WO | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011032050-A2 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | L3MBTL1 3099/4885ACHE 2939/4885POLB 3876/4885 |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | L3MBTL1 1760/4885ACHE 3428/4885POLB 3342/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | L3MBTL1 1080/4885ACHE 3485/4885POLB 3425/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | L3MBTL1 2704/4885ACHE 3720/4885POLB 3511/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | L3MBTL1 4871/4885ACHE 3912/4885POLB 4437/4885 |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | L3MBTL1 3980/4885ACHE 2033/4885POLB 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.